Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Top Selling Peptides September 2026: Research Compound Comparison

The following comparison synthesizes mechanism, research application, and procurement specifications for the leading compounds dominating peptide sales in September 2026. Tirzepatide Dual GIP/GLP-1 receptor agonist Metabolic regulation, weight loss models 5–15

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The following comparison synthesizes mechanism, research application, and procurement specifications for the leading compounds dominating peptide sales in September 2026.
  • Tirzepatide
  • Dual GIP/GLP-1 receptor agonist
  • Metabolic regulation, weight loss models
  • 5–15mg weekly subcutaneous
  • 2–8°C refrigerated after reconstitution
  • Superior metabolic outcomes vs single-target compounds; dual agonism drives 42% YoY growth
  • Semaglutide
  • GLP-1 receptor agonist
  • Cardiovascular outcomes, NAFLD research
  • 1–2.4mg weekly subcutaneous
  • Established safety profile with 8,400+ publications; remains reference standard despite newer alternatives
  • BPC-157
  • VEGF upregulation, NO pathway stabilization
  • Musculoskeletal injury, GI protection
  • 250–500mcg daily subcutaneous
  • Lyophilized −20°C; reconstituted 2–8°C
  • Fastest tissue repair peptide; 43% accelerated healing in tendon injury models
  • Retatrutide
  • Triple GIP/GLP-1/glucagon agonist
  • Advanced metabolic research
  • 4–12mg weekly subcutaneous
  • Cold chain −20°C; highly temperature-sensitive
  • 24.2% weight reduction at 48 weeks; glucagon component enhances thermogenesis beyond dual agonists
  • TB-500
  • Thymosin beta-4; actin polymerization
  • Cardiovascular repair, wound healing
  • 2–5mg twice weekly subcutaneous
  • Essential for cellular migration phase of tissue repair; requires >98% purity to avoid immune response
  • Dihexa
  • HGF mimetic; c-Met receptor binding
  • Neurodegenerative disease, TBI recovery
  • 5mg/kg in rodent models
  • Lyophilized −20°C; light-sensitive
  • 1,000,000× more potent than BDNF for synaptogenesis; reverses age-related spatial memory deficits